Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 04:10PM GMT
Release Date Price: $98.34 (+4.97%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Okay. Hey, everyone, thanks for joining. I'm Marty Auster. I'm the SMID-cap biotech analyst at Crédit Suisse. I've got Doug Ingram, CEO of Sarepta, here with me today. Doug, thanks for coming. Good to see you again.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you very much. Thank you for having us.

Questions & Answers

Martin Douglas Auster;dit Suisse AG;Douglas S. Ingram
CrÃ;Research Division - Research Analyst;Sarepta

© -

We've got a lot of ground to cover and discuss with Sarepta. There's been a lot of stuff since we've seen you last year, and obviously, you just reported the quarter last week. There's some new news from that as well. So we can maybe kind of -- always good to start with kind of an overview of kind of just framing where the company is at now and kind of where you're leading it.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot